Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Branch Chain Amino Acid Clear all
Terminated Phase 1 Interventional

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

NCT01126450
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
lenalidomide, cetuximab, mutation analysis, polymerase chain reaction, polymorphism analysis
Drug · Biological · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 28, 2026, 6:48 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma

NCT03908255
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver Failure
Interventions
Branch Chain Amino Acid, maltodextrin
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule

NCT01502670
View directory record Official record
Conditions
Lung Cancer
Interventions
18F-FACBC Radiotracer
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skeletal Muscle Response to Amino Acids and Load Carriage Exercise

NCT01714479
View directory record Official record
Conditions
Muscle Loss, Muscle Anabolism, Muscle Performance
Interventions
Leucine-enriched nutritional supplement, Placebo
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 28, 2026, 6:48 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Peanut Sip Feeding Protocol

NCT06693544
View directory record Official record
Conditions
Protein Metabolism
Interventions
Peanut protein
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
65 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Early Phase 1 Interventional

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

NCT04740580
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Glycine, N-acetylcysteine, Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851
View directory record Official record
Conditions
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
680
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 28, 2026, 6:48 PM EDT
Not listed Phase 4 Interventional

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

NCT01095822
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aliskiren + Valsartan
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
760
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02766335
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Durvalumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
993
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 623 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 28, 2026, 6:48 PM EDT
Recruiting Phase 3 Interventional

Pivotal Study of N-acetyl-L-leucine for CACNA1A

NCT07221292
View directory record Official record
Conditions
CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
Interventions
N-Acetyl-L-Leucine, Placebo
Drug · Other
Lead sponsor
IntraBio Inc
Industry
Eligibility
4 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

NCT01920711
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protein and Recovery From Exercise-induced Muscle Damage

NCT02034721
View directory record Official record
Conditions
Muscle Damage, Inflammation
Interventions
Protein supplement, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Not applicable Interventional

BCAA Supplemental Study

NCT03339232
View directory record Official record
Conditions
Cirrhosis
Interventions
BCAA Supplement, Physical Activity
Dietary Supplement · Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

NCT01630798
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
GI heptapeptide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 28, 2026, 6:48 PM EDT
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin B6 Effects for Women Taking Birth Control Pills

NCT01128244
View directory record Official record
Conditions
Vitamin B6 Deficiency
Interventions
Vitamin B6, Infusion of labeled serine, methionine and leucine
Dietary Supplement · Procedure
Lead sponsor
University of Florida
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 28, 2026, 6:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients

NCT01172314
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
EAA+LEU vs total AA, Total AA vs EAA+LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 28, 2026, 6:48 PM EDT
Recruiting Phase 4 Interventional

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

NCT07303738
View directory record Official record
Conditions
Feeding Difficulties, Aspiration, Gastrostomy
Interventions
amino acid based formula (e.g. Elecare Jr), low bile acid binding blenderized diet (e.g. Kate Farms), high bile acid binding blenderized diet
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 6:48 PM EDT
Terminated Not applicable Interventional Results available

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01280643
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 28, 2026, 6:48 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

NCT01697930
View directory record Official record
Conditions
Solid Malignancy, Lymphoma
Interventions
[18F] 4-L-Fluoroglutamine (2S,4R)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 28, 2026, 6:48 PM EDT